Search
Fondaparinux
go.drugbank.com/drugs/DB00569ApprovedInvestigationalFondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture, hip replacement and knee surgery); to prevent VTE in … patients undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable
Acetohydroxamic acid
go.drugbank.com/drugs/DB00551ApprovedInvestigationalAcetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. … It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.
Synonyms: N-Hydroxyacetamide, N-AcetylhydroxylaminePariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801Approved[L64050,L64051] It delivers a functional copy of the human G6PC gene, under the control of native G6PC promoter and enhancer elements, to hepatocytes, resulting in the production of normally functioning … [L64050] Restoring hepatic G6Pase activity supports the release of glucose during fasting, and in clinical studies reduced patients' reliance on dietary cornstarch used to prevent hypoglycemia.
Vilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigational[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020. … Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.
Retapamulin
go.drugbank.com/drugs/DB01256ApprovedRetapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.
Talazoparib
go.drugbank.com/drugs/DB11760ApprovedInvestigational[L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020. … [L47301] Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306]
Hydroxychloroquine
go.drugbank.com/drugs/DB01611ApprovedInvestigational[L8072] Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. … [L8072] It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus.
Synonyms: 7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline, 7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinolineSevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608] … Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain
Regorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalApproved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. … Regorafenib is an orally-administered inhibitor of multiple kinases.
Megestrol acetate
go.drugbank.com/drugs/DB00351ApprovedInvestigationalVet approvedAs the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Products: Megex-I Suspension 800mg/20ml